AVITA Medical, Inc. (RCEL) Earnings Call Transcript
May 14, 2026
Earnings Call Speaker Segments
Thanks, operator. I'd like to welcome everyone to AVITA Medical's earnings call for the first quarter of 2026. With me today are Cary Vance, our President and Chief Executive Officer, and David O'Toole, our Chief Financial Officer. You can find today's earnings release and presentation on our website, www.avitamedical.com, in the Investor Relations section. Before we get started, please note that forward-looking statements, as defined under the Private Securities Litigation Reform Act of 1995, are included in this call. Such statements aren't promises or guarantees, and they carry known and unknown risks and uncertainties that might cause actual results to differ materially from any expectations expressed or implied by those forward-looking statements. For full descriptions of the risk factors, please review our most recent filings with the SEC. All forward-looking statements made on this call reflect management's expectations as of today. I'll now hand the call over to Cary.
Good afternoon stateside, and good morning to those of you in Australia. We appreciate you being here. Ahead of discussing the quarter, I'd like to take a moment to note my appointment as President and Chief Executive Officer. During the last 6 months, I've been able to fill this position on an interim basis, collaborating closely with our team, our customers and the Board. I'm grateful for the trust the Board has shown in me after a comprehensive search process, and I'm eager to guide AVITA through this coming chapter. I also want to acknowledge Jan Stern Reed, our new Board Chair. Jan has been strongly involved with the company, and I'm looking forward to collaborating closely with her and the Board as we keep delivering on our priorities. Throughout that same stretch, I've dedicated time to visiting the hospitals that use our products, and to conversations with surgeons. And one thing that's obvious to me is that this business is anything but abstract. Standing in an operating room, you witness directly the partnership we share with surgeons and the part our products play in assisting patients as they recover and get back to their lives; that's what propels our mission. Now to the first quarter. Let me briefly link the quarter to where we've come from, since the movement across the last couple of quarters matters for interpreting what you're seeing in Q1. During the last 2 quarters, we've concentrated on 2 particular priorities: first, getting the business stable. That involved navigating the disruption to clinical reimbursement for RECELL, reengaging our core accounts and restoring a steady, procedure-based demand cadence. Second, enhancing the way we operate; we narrowed our focus onto our highest value centers. We reinvigorated our sales organization and secured a new credit agreement whose terms fit the business and our anticipated revenue trajectory better. Q1 is the quarter in which those changes have started translating into steadier performance. Let me turn to the headline results. As the press release showed, and as this slide reflects, revenue came in at roughly $19.3 million, a rise of 4% year-over-year and about 10% sequentially. That builds on the momentum we had exiting Q4 and marks our strongest quarterly revenue across the last year. David will take you through the complete financials in greater detail. But notably, operating expenses fell year-over-year, which mirrors the cost-saving actions we implemented in the second quarter of 2025, and we are reaffirming full year guidance of $80 million to $85 million. We also observed ongoing progress throughout the business and advances across our product portfolio. I'll address these in my remarks. As we consider the quarter, there are 3 points I'd emphasize. First, the year-over-year comparison remains shaped by earlier ordering patterns. A year ago, the business contained more bulk purchasing behavior, which we don't see now. Second, sequential quarter-over-quarter performance serves as a better signal of underlying demand. Revenue rose roughly 10% versus Q4, as demand for products gathered steam throughout the quarter and carried on into April. Third, and most significantly, the operating cadence keeps getting better. We're observing orders that come more often and in smaller sizes, tighter linkage between what's used and what's purchased, and stronger involvement throughout our key accounts. That points to movement away from the swings of the past and toward steadiness, and in the end, predictability down the road. Now let me walk through a few dynamics in our portfolio. Starting with RECELL. By now, payment rates for clinician use have been published by all 7 Medicare Administrative Contractors. The result we're observing is a steady move back toward utilization patterns driven by procedural demand instead of confusion over reimbursement; you can see that both in renewed participation at the burn centers hit hardest and in quarter-over-quarter gains in ordering and case activity. We're also starting to observe broader use cases, especially involving RECELL GO mini along with smaller burns and trauma settings. Abroad, fresh regulatory clearances in Australia and New Zealand put us in position to grow RECELL GO in those markets. Also, over the quarter, we disclosed a new long-term arrangement with BARDA aimed at backing U.S. burn emergency preparedness. That extends a partnership of long standing and captures the part RECELL may play in a mass casualty response, where quick treatment and the ability to scale matter greatly. Commercially speaking, this delivers a modest amount of recurring readiness revenue and simultaneously strengthens how essential RECELL is within the wider health care system. More broadly, it highlights the clinical relevance and dependability of the platform in high-acuity settings, plus the trust a key government partner places in our capacity to deliver at scale. So pulling back, RECELL stays the bedrock of the business and is once more a utilization driver as we grow throughout our accounts. Now let me shift to Cohealyx. Commercially, Q1 amounts to early stage adoption with signals that are encouraging. We noticed, for instance, a growing count of ordering accounts as VAC approvals move forward and early repeat usage among initial adopters. That matches what should be expected at this point in a product life cycle. One key development during the quarter came from interim clinical data in the Cohealyx-I study. Broadly speaking, the data reveals a substantial cut in time to graft readiness, roughly 20 days against benchmark, with outcomes consistent across patients. We likewise observed a median time to grafting of about 11 days. In some cases early grafting happened within the first week, alongside high levels of investigator satisfaction. Significantly, this data set is now backing ongoing VAC reviews, which helps bolster the clinical value proposition as hospitals weigh adoption. We also keep receiving favorable feedback from clinicians already using Cohealyx, especially regarding consistency of outcomes, which is feeding into early repeat use. Later this year, we anticipate having the complete data set, and that represents a significant next step toward enabling wider adoption. I'd also point you toward the key opinion leader webinar from April, which you can find on our website. During that session, the data gets a much closer look. Just as importantly, it shows the way Cohealyx fits into surgical workflows, such as when it's used together with RECELL in staged procedures. Last, a word on PermeaDerm. Commercially speaking, things are still evolving. During this quarter, we rolled out a new clinical positioning against cadaveric allograft, centered on serving as a more cost-effective biosynthetic option for wound coverage and healing. Later this year, we anticipate results from the PermeaDerm-I study; early indicators, histology among them, point to biological performance on par with cadaveric allograft. Thus, much like Cohealyx, PermeaDerm's near-term purpose is establishing clinical confidence, a clear place in the treatment pathway, and surgeon familiarity. Our showing at April's American Burn Association Annual Meeting was robust, and that gathering continues to be the premier clinical and commercial venue for our business. Engagement throughout the portfolio really stood out this year. Scientific participation was wide, clinical interaction proved meaningful across numerous forums, and talk kept growing about how our products work together in practice. Crucially, this went beyond mere awareness — it was genuine clinical dialogue spanning education, case sharing, and surgeon feedback. So what we take away from this year's ABA Conference is that clinical engagement keeps expanding and our integration into clinical discussions and workflows keeps deepening, backed by data as well as real world experience. To sum up, across the last 2 quarters, we've steadied the business and sharpened our operations. What's emerging now is more dependable utilization throughout our accounts, with initial hints of growth as that groundwork solidifies. Meanwhile, the momentum from ABA, along with the Cohealyx clinical data, underscores the clinical differentiation and worth of our platform. Looking toward Q2, we're concentrating on sustained sequential growth, fueled by rising utilization throughout our core burn and Tier 1 trauma accounts, while proving our progress can be repeated. With that, I'll pass it to David for a closer look at the financials.
I appreciate that, Cary, and hello everyone. As Cary explained, Q1 shows ongoing advancement as we transition out of stabilization and into a phase of the business more centered on execution. In my remarks today, I'll walk through how that advancement appears in our financial outcomes for revenue, gross margin, operating expenses and cash. Starting with revenue. For Q1, total revenue came in at roughly $19.3 million, which is 4% growth compared with the same period a year ago and about 10% growth sequentially versus the fourth quarter of 2025. The quarter's growth came from contributions by Cohealyx, RECELL GO mini and better RECELL utilization as reimbursement dynamics keep normalizing. Notably, ordering patterns are increasingly matching the procedural demand underneath them. That is helping revenue become more consistent, with sales performance gaining strength during the quarter and carrying momentum as March ended; given our Q1 results, we are reaffirming our full year 2026 net revenue guidance of $80 million to $85 million. Moving to gross margin. For the quarter, gross profit margin was 81.7%, versus 84.7% in the prior year period. The difference came mainly from certain required inventory reserves and product mix, as Cohealyx and PermeaDerm made up a larger share of revenue. As we've said before, although this product mix shift affects the reported gross margin percentage, these products bring in incremental gross profit without a proportional rise in operating expenses. Consequently, they stay accretive to absolute gross dollars and help operating leverage over time. In line with the framework we laid out with our broader portfolio as we came out of 2025. RECELL gross margin stayed strong at roughly 85% and we anticipate that continuing. Moving to operating expenses. Total operating expenses were $24.5 million, an 11% decline year-over-year. That shows continued execution on the cost optimization initiative, including the sales force transformation carried out in 2025, and confirms that we are running with a lower and more disciplined cost base. Importantly, this structure is now stable and matched to the business's current scale. As revenue increases, we expect this to enable better operating leverage. For the quarter, net loss was $10.6 million or $0.35 per basic and fully diluted share, an improvement relative to $13.9 million or $0.53 per basic and fully diluted share in the prior year period. Now moving to cash, which we recognize as a key focus. Net cash used for the quarter was approximately $9.9 million. As anticipated, cash use was greater in Q1 because of seasonal compensation and other onetime payments, and it was pushed even higher by the timing of revenue and collections. Cash receipts clearly trailed revenue, and since a larger share of product sales happened later in Q1, our cash receipts took a negative hit, which raised our cash use. As we enter the second quarter, these timing dynamics have flipped. One-time and seasonal matters are now behind us, and cash receipts are rising thanks to collections from a robust finish to the first quarter and sales activity early in the second quarter. Alongside continued discipline on costs, that combination leaves us quite confident that cash used in the second quarter will fall substantially. We closed the quarter with roughly $14.3 million across cash and marketable securities. On the debt facility side, we continue to satisfy the trailing 12-month revenue and minimum cash covenants in our credit facility, and those covenants line up with the operating path we are on now. It matters that this facility, arranged in January with Perceptive Advisors, was built to allow more flexibility than the credit agreement it replaced, with covenant thresholds placed well under the annual revenue we expect and a lower minimum cash requirement. With that much headroom, we would not anticipate the revenue covenants in this agreement becoming an area of focus down the road. To give some context, the second quarter trailing 12-month revenue covenant of $69 million works out to a second quarter revenue requirement of just $15 million, still far beneath the quarterly revenue we have posted lately. The structure carries interest only and comes with extra capacity contingent on hitting a defined revenue milestone. Considered together, those terms were crafted to enable execution instead of holding it back, offering better visibility and headroom while we scale the business. Consequently, we think our present capital structure lines up well with the operating plan, which underpins our capacity to run the business for ongoing growth, stronger cost efficiency and, in the end, financial sustainability. In short, we are posting sequential quarterly revenue growth alongside demand consistency that keeps improving, an operating cost structure that is stable and disciplined, and clear visibility into reduced cash use as we enter the second quarter. Those pieces show ongoing execution against the framework we set out in 2025 and sharpen our emphasis on consistent, repeatable performance throughout the year. With that, I'll turn things back over to Cary.
Thanks, David. To give a quick recap of quarter one: we turned in a strong top-line result in Q1, helped along by better RECELL utilization. As the quarter closed, we saw procedure-driven demand becoming more and more steady throughout our core accounts. We produced persuasive Cohealyx clinical data that underscores how it stands apart from other dermal matrices. And we bolstered our leadership as we change gears entering this next stage of our AVITA journey. Looking toward Q2, our focus is plain: generate sequential growth and show recurring progress throughout our business. With that said, let's open it up for questions.
Frank, thanks — glad you thought Q1 was solid. To kick things off, I wanted to ask something about the mix. If you're willing to share how it splits between RECELL and Cohealyx, that would be terrific. If that's not possible, then as a fallback I'd ask which of those 2 contributed more to the growth — was it RECELL bouncing back, or Cohealyx ramping up quite fast?
Look, we aren't breaking that out at this point. Still, Frank, it came from both of them together. RECELL went up, and Cohealyx went up; those 2 are the primary growth engines.
All right, that's useful. Regarding the prepared remarks, I believe you mentioned that sequential growth for Q2 is still anticipated. Could you expand on that a bit? And clearly, the quarter came in somewhat above what Street expectations had been, and we get the desire to only issue expectations you can hit. But perhaps walk us through how you considered possibly raising the guide a little, simply because the recovery in Q1 appears to be going so well.
Yeah. What I'd say is, at this moment we are holding to the guidance. Still, I genuinely believe this is a business that compounds on its own momentum. Much of the effort we put in, including during the latter part of 2025, delivered the Q1 results; and I anticipate that effort carrying forward. Beyond generating orders and revenue, plenty of solid work got done. Numerous things were built. There were hospitals that emerged from VAC around Cohealyx. So behind the revenue figure, there's substantial progress happening behind the scenes. And we anticipate holding onto that type of progress from Q1 into Q2 and securing 3 months of it rather than perhaps a month or 2 of it, which happened when we brought a new physician or new procedures on board in Q1. Thus we expect it to compound on its own momentum, roughly quarter-over-quarter. That's the reason we describe it that way. So expect more in a few months.
Cary, David, congratulations on the progress. To move past this topic, Cary, regarding the MAC dynamics. I'm grateful you mentioned that the 7 MACs are now publishing rates. I do want to verify, however, past the published rates, the seventh MAC you were awaiting, everyone is now fully reimbursing for RECELL at this point, correct?
That is correct. Thanks, Ryan; so all of them have published and there was 1 MAC where the rates were — the rate was below the others and they've brought that rate up in line with everyone else.
Alright, that's quite useful and encouraging to hear. Regarding — and this only makes up one portion of what I want to ask, plus I'll have a follow-up about BARDA. You said something about utilization, and about how smaller burns are starting to see some uptake. So I'd like to know what's behind that. Is it that you're deliberately going after lower TBSA burns since those happen more often? And if so, that would imply physicians are growing more at ease with the RECELL device. Could you address that? And as I mentioned, I've got just one brief item about BARDA.
Well, clearly, we want them applying it to each wound and every burn size. With clinicians, the recurring issue is whether it's worthwhile. Worthwhile from a cost standpoint? Worthwhile when it comes to the hours required and the workflow? So I'd say several factors are at play. From a clinical angle, we keep demonstrating and persuading them further that the effect on healing and on pigmentation justifies it for the patient. With an option like RECELL GO mini — cheaper, and genuinely built for smaller wounds — plus the financial effect of length of stay, or the benefit to the patient, the hospital, and honestly everybody concerned from faster healing, I believe it's finally beginning to land. Essentially, we're attempting to cover every base when it comes to objections or explanations for not using it. Through technology and through data — economic as well as clinical — we're working to tackle each of them.
All right. For the final one, this may be directed more at David, though regarding the BARDA contract, my understanding is that it could reach as much as $25.5 million in revenue — possible revenue. If I recall correctly, $3.5 million of that is assured. So, David, what's your thinking on how that will flow in once it does arrive? Any sort of guidance on that would be really useful. Thanks.
Of course, Ryan. Nice to hear from you, and I appreciate you asking. The portion that's assured is roughly $3.9 million across 10 years. Essentially, that gets amortized each month throughout that 10-year stretch. So it's fair to figure on roughly $100,000 every quarter, and about $30,000 per month. Billing happens on a monthly basis. That means the cash arrives over the course of that 10-year span. The remaining portion applies only in the event of a mass casualty. What we're obligated to do is keep safety stock. We have to hold stock available, yet it amounts to the safety stock we'd maintain regardless. Therefore, there's no increase, and since I've gotten this question previously, I'll simply state that maintaining that safety stock, which satisfies what BARDA requires of us, does not raise our costs.
Just a quick one. When it comes to the guidance, given all the different pieces in play right now with the product mix, what drivers would you point to that might lead us to think the company could land at the high end of guidance for the year? What — given the Cohealyx data and everything else, what should we keep in mind?
Well, I think we have — thanks, Chris. Good to hear from you. I think we've got 1 quarter behind us, right? And so I think even though I and the team feel a good sense of confidence, me 6 months into the role, about where we stand, what we know, how what we're doing is affecting the market and the number, it's still only a quarter. And I think for us, it's a question of watching the progress over the course of the year. That will give us a better level of confidence and visibility into where we'd expect to end the year. And my expectation is we're going to be as transparent as we can about how we're progressing and what we expect, and that we'll report out accordingly.
Great. And as a quick follow-up on those smaller orders we're currently seeing, could you tie that back to — is it because of a shift in the sales team's approach and/or staffing? Any thoughts there would help.
Sure. Our view is that customers should be able to place orders in whatever manner suits them, both in terms of the quantity they keep on hand and how frequently they go through it. We're reacting to what they want. We also want to be certain that we aren't imposing our own preferences, such as a desire for bigger orders, since that doesn't actually assist us in smoothing things out. What I appreciate on the AVITA side of this is that it turns into something highly consistent and highly predictable. And as we conduct weekly, regular forecasting exercises, we're getting really adept at grasping the way our customers purchase and anticipating the way they'll purchase in the weeks and months ahead within the quarter. And once more, we wouldn't operate that way if our customers didn't prefer it. So it's truly a mix of giving them — allowing them to order and use things however they wish, plus us having a mechanism and a process that keeps us highly predictable.
One final item for David. David, regarding taking costs out, is there any room left to trim? Should we assume the expense line holds steady going forward?
Correct. The way to view it is that our cost structure has been stabilized, which I've mentioned before. The single item I'd like to see rise is commissions, since that's the thing that will signal we're bringing in greater revenue. Still, when it comes to G&A and R&D and headcount, our cost structure sits exactly where we want it.
Congrats once more, Cary, on having the interim label taken off your CEO position. I wanted to kick things off — I realize you fielded a few questions about MAC and you walked through how the 7 MAC publishing is progressing. Could you help us consider how physician confidence and/or centric burn center confidence looks when it comes to receiving reimbursement for RECELL at this stage? You figure we're at 50% to 75% VAC. I understand you're counting on steady sequential improvement throughout this year. But perhaps walk us through where things stand on that rebound regarding physician and center confidence that reimbursement will come through.
Yes. I'd put it at 75%, which is probably a solid figure. And like we've discussed across the last 3, 5 months, I've more or less been saying that's how it would play out. You've got the formal MAC circumstances, and separately there's education and communication work that has to happen so we get back to the position we held more than a year ago. Part of it is that. And another part is that at present, we're in something of a blocking and tackling mode health care system — one health care system or hospital at a time, since each has its own internal discussion regarding what gets reimbursed and the way to obtain reimbursement. So we're simply assisting with educating everyone on all of that, which we likely would have been doing more of 12 months back if this MAC problem hadn't arisen, correct? So at this point, once that has been more or less formally resolved, we now proceed hospital by hospital alongside our health care access team and our commercial teams to confirm they grasp how they get paid and how to navigate the process.
So, right after ABA, with the Cohealyx news, I was hoping — obviously that product is generating more excitement — but I was hoping you might sharpen the picture a bit on what traction looks like, since it's still early days following ABA, and whether there's any surgeon feedback. Then, could you also share whatever updates you have on how many centers have begun adopting the full portfolio — RECELL, Cohealyx, and PermeaDerm — and what early traction you're seeing as the portfolio expands?
Absolutely. I'll take the second question first. In terms of centers utilizing all 3 products, I believe we're in the 20s. Again, if you haven't had the chance, on our website there's a terrific webinar we held during ABA featuring me and Katie — Dr. Katie Bush — plus 2 of our physicians, and they described far better than we ever could the everyday use, utilization, and workflow for Cohealyx and PermeaDerm, along with the study and some of its results, because both of those things matter. Naturally, data matters, but so does the daily, hands-on experience and the credibility those physicians bring. I'd encourage all of you to go back and listen if you haven't yet; but I think a substantial amount of buzz has come out of ABA, the study itself, and the preliminary release. My sense is that this speeds things up somewhat with our VAC committees. That's just an instinct — if they have superior and additional information during the process, it should move through faster; we're eager to be competitive. When compared with other dermal matrices, Cohealyx looks quite strong in my view. There are certain edges we have as well. And our goal is simply to get moving on that. Still, achieving it requires — this data is going to be a big help, and so will actually getting past VAC and bringing in more users who can share feedback and act as reference sites, which lets others see why Cohealyx is worth choosing. So I'd say that's obvious, and it's thrilling. I can't wait for what's coming in the next few months, because my expectation is that Cohealyx will emerge from somewhere between 12 and 15 VACs each quarter. That's about the same as what we saw in the prior quarter. That's one more thing I'm anticipating this quarter, and I anticipate it will keep going. Somewhere around 55 to 60 of them remain in VAC. Whenever a few come out, additional ones go back in, which is fantastic, since eventually we'll have coverage across every burn center and Level 1 trauma center, and we'll be cleared to compete in all of them.
Appreciate it, operator, and I want to thank all of you for making time and showing your support today. We're eager to keep up the engagement and conversations with each of you over the days and weeks ahead, and we're excited about delivering yet another strong quarter. Thank you, everybody.
This concludes today's conference call. Thank you for participating, and you may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete AVITA Medical, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to AVITA Medical, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.